HC Wainwright Estimates Kairos Pharma Q1 Earnings

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Kairos Pharma in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright also issued estimates for Kairos Pharma’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.12) EPS.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter.

Kairos Pharma Stock Performance

Shares of KAPA opened at $0.58 on Friday. Kairos Pharma has a 12 month low of $0.40 and a 12 month high of $2.11. The stock has a market capitalization of $12.44 million, a price-to-earnings ratio of -1.94 and a beta of 1.97. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.83.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in shares of Kairos Pharma in the second quarter worth about $44,000. Two Sigma Investments LP bought a new stake in shares of Kairos Pharma during the 3rd quarter valued at approximately $54,000. Finally, FNY Investment Advisers LLC acquired a new position in Kairos Pharma during the 3rd quarter worth approximately $27,000.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.